InvivoGen Limited

Innovation within Reach

InvivoGen has been involved in handling microbes to produce a wide range of biological molecules for over forty years. In 1970s, Dr. Gérard Tiraby, the founder of InvivoGen and the professor of microbiology at the Université Toulouse III, discovered a unique antibiotic and named it Zeocin®; an anti-mycoplasma antibiotic, Plasmocin®, was also developed in the early 1980s and has been widely used by researchers to prevent or remove mycoplasma contamination in cell culture. In 1997, there was a ground breakthrough in the research of innate immune sensors. Thanks to our unique knowledge in microbiology, InvivoGen was the first to commercialize Toll-Like Receptors (TLRs) ligands in 2000 and has become the supplier with the most comprehensive range of products for innate immunology research.

As innate immunity expands to interdisciplinary field of study. InvivoGen therefore keeps enlarging our library of products and services for different research fields such as cancer immunotherapy, gene therapy, cell therapy, vaccine development and bioactivity screening for artificial intelligence drug discovery, etc.


InvivoGen’s Life Science Research Products

Tools for detection and elimination of microbial contaminants

Selective antibiotics

Pattern recognition receptors (PRR) agonists and antagonist

Genes and proteins related to immunology

Reporter cell lines
Immune checkpoint antibodies

Vaccine adjuvants
COVID-19-related products